Sujet(s)
Paralysie périodique hypokaliémique , Thiamazol/administration et posologie , Métoprolol/administration et posologie , Potassium , Tachycardie sinusale , Hormones thyroïdiennes/sang , Thyréotoxicose , Adulte , Antiarythmiques/administration et posologie , Antithyroïdiens/administration et posologie , Humains , Paralysie périodique hypokaliémique/diagnostic , Paralysie périodique hypokaliémique/traitement médicamenteux , Paralysie périodique hypokaliémique/étiologie , Paralysie périodique hypokaliémique/métabolisme , Mâle , Force musculaire , Potassium/administration et posologie , Potassium/sang , Tachycardie sinusale/diagnostic , Tachycardie sinusale/traitement médicamenteux , Tachycardie sinusale/étiologie , Glande thyroide/imagerie diagnostique , Thyréotoxicose/complications , Thyréotoxicose/diagnostic , Thyréotoxicose/traitement médicamenteux , Thyréotoxicose/métabolisme , Résultat thérapeutique , Échographie/méthodesRÉSUMÉ
Ovarian cancer presents a diagnostic challenge because of its subtle clinical presentation and elusive cell of origin. Two new technologies of proteomics have advanced the dissection of the underlying molecular signaling events and the proteomic characterization of ovarian cancer: mass spectrometry and protein array analysis. Mass spectrometry can provide a snapshot of a proteome in time and space, with sensitivity and resolution that may allow identification of the elusive "needle in the haystack" heralding ovarian cancer. Proteomic profiling of tumor tissue samples can survey molecular targets during treatment and quantify changes using reverse phase protein arrays generated from tumor samples captured by microdissection, lysed and spotted in serial dilutions for high-throughput analysis. This approach can be applied to identify the optimal biological dose of a targeted agent and to validate target to outcome link. The evolution of proteomic technologies has the capacity to advance rapidly our understanding of ovarian cancer at a molecular level and thus elucidate new directions for the treatment of this disease.
Sujet(s)
Tumeurs de l'ovaire/diagnostic , Tumeurs de l'ovaire/génétique , Protéomique , Analyse chimique du sang , Femelle , Humains , Spectrométrie de masse , Tumeurs de l'ovaire/sang , Tumeurs de l'ovaire/composition chimique , Analyse par réseau de protéinesRÉSUMÉ
Teratomas are embryonal neoplasms which arise from totipotential cells and contain elements from all three germ layers (ectoderm, mesoderm, and the endoderm). Simultaneous occurrence of mediastinal and gastric teratomas in infants has not been reported, although gastric teratomas extending into the mediastinum have been reported twice in literature. We report here a case in which a gastric cystic teratoma was connected to its mediastinal counterpart with a pedicle. The pertinent literature is reviewed.